PubMed Health⌕ Search

Biomedical subjects

D Weissmann

Publications and source records attributed to D Weissmann.

38 records · Page 3Linked to original sources

Benzodiazepine binding sites in the cingulate cortex after lesion of the noradrenaline and dopamine containing afferents.

The distribution of benzodiazepine binding sites was analysed in the cingulate cortex of the rat brain by quantitative radioautography of brain sections incubated with a full agonist benzodiazepine ligand, 3H-flunitrazepam (3H-FLU), or with a partial agonist with non benzodiazepine structure, (7-3H)-4hydroxy-N(4,5-dihydroxy-2-thiazolyl)-6 methoxy-3-quinoline (3H-RU 43028), after lesion of noradrenaline (NA) and dopamine (DA) containing afferents to this structure. NA denervation was obtained by systemic administration of N-(2-chlorethyl)-N ethyl-2-bromobenzylamine (DSP4) and destruction of both NA and DA containing afferents was induced by unilateral injection of 6-hydroxydopamine (6-OHDA) in the middle forebrain bundle (MFB). A similar caudo-rostral pattern of distribution was found in the cingulate cortex after incubation with these two ligands which bound a greater number of sites in the anterior portion of the structure. In spite of a very precise anatomical sampling (200 micron intervals along the postero-anterior axis) no significant difference was observed when intact and lesioned brains were compared. It is concluded that benzodiazepine binding sites eventually localized on catecholaminergic afferents to the cingulate cortex do not represent a significant proportion of the total population of these sites in this structure.

Afferent Pathways↗

Regional distribution of high-affinity gamma-[3H]hydroxybutyrate binding sites as determined by quantitative autoradiography.

The distribution of high-affinity binding sites for gamma-[3H]hydroxybutyrate in coronal sections of rat brain was studied by quantitative autoradiographic techniques. Binding sites for this naturally occurring substance, which may possibly have a neurotransmitter role, are concentrated in some restricted areas of the brain, particularly in the limbic system. The hippocampus (especially field CA1 of Ammon's horn, at 292 fmol/mg of tissue), septum (72 fmol/mg of tissue), and cortex (frontal, 113 fmol/mg of tissue; parietal, 103 fmol/mg of tissue; cingulate, 114 fmol/mg of tissue; and entorhinal, 134 fmol/mg of tissue) show pronounced labeling with gamma-[3H]hydroxybutyrate. Binding is much lower in caudatus-putamen (50 fmol/mg of tissue), thalamus, and hypothalamus. Caudal parts of the brain (cerebellum, pons, and medulla) are practically devoid of binding sites. These results strongly support a functional role of endogenous gamma-hydroxybutyrate in particularly restricted areas of the rat brain.

Animals↗